Low expression of GNAI3 predicts poor prognosis in patients with HCC

Guodong Chen; Xiaoyan Li; Gengsheng He; Zijian Yu; Jiaxing Luo; Jun He; Zonghai Huang
December 2015
International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 11, p21482
Academic Journal
Purposes: This study was performed with an aim to explain the underlying role of GNAI3 on the prognosis of patients with HCC. Methods: The expression of GNAI3 at protein level was detected with the utilization of Immunohistochemistry (IHC). Chi-square test was conducted to assay the relationship between GNAI3 expression and clinical parameters of HCC patients. The correlation between expression level of GNAI3 and survival time after surgeries of HCC patients was evaluated by Kaplan-Meier method. Finally, the Cox regression was established to evaluate the relationship between GNAI3 expression and the prognosis of patients with HCC. Results: In this study, the negative rate of GNAI3 expression in HCC samples was about 76.6%, which was significantly higher than that in paired normal specimens (12.5%). Result showed that there was no correlation between GNAI3 expression and age, gender, liver cirrhosis and vein invasion (P>0.05), but tight relationship between GNAI3 expression and TNM stage and tumor size was found (P<0.05). The following Kaplan-Meier analysis result illustrated that negative expression of GNAI3 induced high mortality of HCC patients. Cox regression result revealed that GNAI3 might be a biomarker for prognosis of patients with HCC (HR: 0.218, P=0.016, 95% CI 0.063-0.750). Conclusion: Generally, results of this study demonstrated that expression of GNAI3 shared a tight relationship with the prognosis of patients with HCC. Therefore, GNAI3 could be considered as a novel index for prognosis of patients with HCC.


Related Articles

  • Correction: Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study.  // CMAJ Open;Oct2015, Vol. 3 Issue 4, pE359 

    A correction to the article "Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study" that was published in the 2015 issue is presented.

  • International pediatric liver cancer pathological classification: current trend. Tanaka, Yukichi; Inoue, Takeshi; Horie, Hiroshi // International Journal of Clinical Oncology;Dec2013, Vol. 18 Issue 6, p946 

    This review describes the pathological classification of pediatric liver cancer types and subtypes proposed at the recent international symposium (March 2011, Los Angeles, USA) and meetings involving pathologists serving as central reviewers for the Children's Oncology Group, Société...

  • Function and clinical potential of microRNAs in hepatocellular carcinoma (Review). LIJUAN WANG; YONGFANG YUE; XIAN WANG; HONGCHUAN JIN // Oncology Letters;Dec2015, Vol. 10 Issue 6, p3345 

    MicroRNAs (miRNAs) are small non-coding RNAs involved in the initiation and progression of several types of human cancer, including hepatocellular carcinoma (HCC), which is one of the most common types of cancer and the third leading cause of cancer-related mortality worldwide. Mounting evidence...

  • Infantile hepatic hemangioendothelioma: Report of two cases. Dobanovački, Dušanka; Vučković, Nada; Marinković, Smiljana; Kolarović, Jovanka; Stefanović Saravolac, Svetlana // Archive of Oncology;2013, Vol. 21 Issue 2, p72 

    We described two cases of infantile hepatic hemangioendothelioma: one with a solitary lesion and the other with multicentric lesions. Clinical presentation was with no liver symptoms in case 1, and hepatomegaly, failure to thrive, and palpable abdominal mass in case 2. Diagnostic imaging...

  • Liver cancer. Gravitz, Lauren // Nature;12/4/2014 Supplement, Vol. 516 Issue s7529, pS1 

    The article offers an introduction to the issue in which the editor discusses liver cancer, its diagnosis and survival rates of patients who contract it.

  • A 18F-FDG PET/CT Screening Study of a Hepatocellular Carcinoma Patient with Diffuse 18F-FDG Uptake into the Portal Vein and its Intrahepatic Branches. Koroglu, Reyhan; Koksal, Ismail; Gezer, Fatma; Kahraman, Aysegul; Kekilli, Ersoy // World Journal of Nuclear Medicine;Jan-Apr2016, Vol. 15 Issue 1, p68 

    Major vascular invasion is one of the worst prognostic factors of hepatocellular carcinoma (HCC). Fludeoxyglucose F 18 (18F-FDG) positron emission tomography/computed tomography (PET/CT) method is succesfully being used in HCC patients for the detection of particularly long-distance metastasis....

  • General Evaluation of Hepatectomy and Hepatocellular Carcinoma Cases. BAŞSÜLLÜ, Nuray; TÜRKMEN, İlknur; YAPRAK, Onur; DAYANGAÇ, Murat; DEMİRBAŞ, Tolga; GÜLER, Necdet; URAZ, Süleyman; AKYILDIZ, Murat; CİĞERCİOĞULLARI, Engin; TOKAT, Yaman; YÜZER, Yıldıray; BÜLBÜL DOĞUSOY, Gülen // Turkish Journal of Pathology;2011, Vol. 27 Issue 3, p221 

    Objective: Although the clinical and histopathological findings of hepatocellular carcinoma are well described, there are few national studies. In this study, we aimed to investigate the relationship between these findings in total or partial hepatectomy specimens in our series. Material and...

  • Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. Seung Up Kim; Jeon Han Park; Hyon-Suk Kim; Jae Myun Lee; Hyun Gyu Lee; Hyemi Kim; Sung Hoon Choi; Shinhwa Baek; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Jong Doo Lee; Kwang-Hyub Han // Yonsei Medical Journal;Sep2015, Vol. 56 Issue 5, p1296 

    Purpose: Dickkopf-1 (DKK-1) is a Wnt/β-catenin signaling pathway inhibitor. We investigated whether DKK-1 is related to progression in hepatocellular carcinoma (HCC) cells and HCC patients. Materials and Methods: In vitro reverse-transcription polymerase chain reaction (RT-PCR), wound healing...

  • Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. WENMIN HOU; JIBIN LIU; PEIZHAN CHEN; HUI WANG; BANG-CE YE; FULIN QIANG // Oncology Letters;2014, Vol. 8 Issue 3, p1249 

    The RAS/RAF and PI3K/PTEN signaling pathways play central roles in hepatocarcinogenesis. KRAS, NRAS, HRAS, BRAF, PIK3CA, PIK3R1 and PTEN are key cancer-related genes in the RAS/RAF and PI3K/PTEN signaling pathways. Genetic alterations in these genes often lead to the dysregulation of the two...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics